August 5, 2022 06:37 AM EDTUpdated 12:59 PM
Peer Review

Astel­las taps sea­soned CMO amid shift to on­col­o­gy; Doug Man­ion steps in­to a new Are­na fol­low­ing $6.7B buy­out

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Amber Tong

As Bern­hardt Zei­her re­tires from Astel­las’ chief med­ical of­fi­cer po­si­tion, the se­lec­tion of his suc­ces­sor says a lot about the changes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

BioN­Tech says VEGF bis­pe­cif­ic’s PD-L1 tar­get, com­bo plans will be its edge

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times